KRAS mutant inhibitor QTX3544

An orally bioavailable allosteric dual ON/OFF state inhibitor of multiple oncogenic KRAS mutant forms, particularly KRAS G12V, with potential antineoplastic activity. Upon oral administration, KRAS mutant inhibitor QTX3544 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.